Abstract
Reperfusion of ischaemic intestine is characterised by an initial hyperaemia with ensuing mucosal repair. This study investigated possible roles for gut vasoactive neuropeptides and trophic peptides in these phenomena. Groups of rats were monitored during superior mesenteric artery occlusion for five or 20 minutes, with or without subsequent reperfusion for five minutes. Peptide concentrations (fmol/ml) in arterial blood, were measured using specific radioimmunoassays. Intestinal ischaemia alone did not cause haemodynamic disturbance or peptide release. Reperfusion, after five minutes of ischaemia, resulted in arterial hypotension and a rise in plasma vasoactive intestinal polypeptide (mean (SEM)) (37 (3), control 11 (4), p<0O001). After actions of somatostatin.6 The second aim of this study was, therefore, to monitor the plasma release of enteroglucagon and bombesin in response to intestinal ischaemia/reperfusion.
Methods
Five groups of male Wistar rats (n=6 per group), weighing 280-320 g, deprived of food for 12 hours but permitted free access to water, were studied. Animals were anaesthetised with an intraperitoneal injection of a mixture of fentanyl 0-2 mg, fluanisone 5 mg, midazolam 3 mg, and allowed to breathe spontaneously. Further doses of anaesthetic were given during the experiment as required. Animals were placed on a thermal blanket to ensure a constant body temperature between 37°C and 380C.
EXPERIMENTAL PROTOCOL
A cannula, inserted into the lower abdominal aorta through the left femoral artery, was connected to a PT400 pressure transducer (Palmer Bioscience, Sheerness, Kent, England) for continuous monitoring of the arterial blood pressure and heart rate. (2) 158 (27) Plasma peptides are mean (SEM) fmol/ml.
respectively. The fall in systolic (p<0 005) and diastolic (p<0 05) blood pressure in the 20 VR was significantly greater compared with the 5 I/R animals. There was no overall change in heart rate with either ischaemia alone, or during reperfusion.
PLASMA PEPTIDES
The plasma concentrations of a-CGRP, substance P, neuropeptide Y, peptide YY, and somatostatin did not change significantly in any of the experimental groups, compared with control (Table I) . By contrast, there were significant changes in the plasma concentrations of VIP, 13-CGRP, bombesin, and enteroglucagon. Table II shows that significant increases in the plasma peptides occurred only as a result of ischaemia/reperfusion and not with ischaemia alone. Plasma VIP (Fig 2) nearly trebled in the 20 I/R and more than trebled in the 5 I/R animals. Similarly, enteroglucagon (Fig 3) increased by more than two and three times in the 5 I/R and 20 I/R groups, respectively. Plasma concentrations of 1-CGRP (Fig 4) and bombesin (Fig 5) roughly doubled in the 20 VR animals. In contrast with VIP and enteroglucagon, however, there were no increases in plasma 1-CGRP or bombesin in the 5 I/R animals.
Strong correlations were shown between the plasma concentrations of bombesin and enterglucagon (r=0-76), and of VIP and enteroglucagon (r=0-71). In addition, good correlations were obtained between all the peptides whose plasma concentrations changed as a result of ischaemia/reperfusion (Table III) . There was also a strong correlation, however, between cx-and 1-CGRP (r=0-72) and a weaker correlation between VIP and a-CGRP (r=0 43) despite the lack of overall change in ao-CGRP concentrations. obtained, their tissue of origin cannot be precisely determined. The intestine is, however, by far the richest source of these neuropeptides4-6 16 17 and raised concentrations of VIP have been reported in the portal vein during intestinal ischaemia.'0-12 The neuropeptides probably accumulated in the ischaemic intestine and were washed out into the peripheral circulation during reperfusion. Therefore these putative neurotransmitters,8 14 located in enteric primary autonomic neurons,4 5 17 could be released during ischaemia by a local axon reflex mechanism after activation of chemosensitive mucosal receptors.18 34 This seems a more plausible explanation than speculating peptide release from an extraintestinal source, secondary to systemic hypotension. Thus, if present in the ischaemic gut at the onset of reperfusion, they may be implicated in important pathophysiological events. These powerful mesenteric vasodilators8 15 facilitate tissue perfusion and potentiate fluid and protein extravasation. 35 36 Consequently, they may promote the generation of oxygen free radicals by xanthine oxidase24 and foster an environment favourable to neutrophil activation, leading to reperfusion injury.37 Although these actions must remain speculative both VIP and ,B-CGRP are active at the plasma concentrations measured here13 14 38 39 and much higher concentrations can be achieved at neuroeffector junctions.8 14 38 In this study the plasma concentrations of the other mesenteric vasodilator neuropeptides ot-CGRP and substance P did not rise. In view of the observed correlation between ot-and 1-CGRP, however, it is possible that ot-CGRP was also released from perivascular nerves15 16 but remained tightly bound to tissue receptors.14 Substance P, another putative intestinal vasodilator3 18 19 is active after endoluminal release,40 which might explain why its plasma concentrations did not rise. Alternatively, differences in tissue distribution and concentration of these neuropeptides may account for the discrepancies in their plasma responses. Within the enteric nervous system VIP is the most abundant neuropeptide4-6 and there is a much larger population of intrinsic 1-CGRP compared with extrinsic a-CGRP neurones.17
There is also a far richer supply of CGRP in mesenteric vascular nerves compared with substance p'6 whose neurons are mainly distributed in the myenteric plexus6 where they may be protected from ischaemia. By contrast, VIP and r-CGRP neurons are abundant in the mucosa/submucosa, regions susceptible to the effects of ischaemia.24 37 Plasma peptide YY, a potent splanchnic vasoconstrictor peptide,22 remained unaffected by intestinal ischaemia/reperfusion. As peptide YY is mainly found in colonic mucosal cells,2241 its previously reported release may have resulted from prolonged ischaemic injury to the distal bowel.'1 Neuropeptide Y, a potent vasoconstrictor neuropeptide20 of intrinsic and extrinsic enteric nerves,21 was not released from the reperfused intestine in agreement with the earlier study. 1' Plasma concentrations of somatostatin, another vasoconstrictor neuropeptide evenly distributed throughout the small bowel,23 did not rise either. The lack of vasoconstrictor response contrasted sharply with the rise in plasma vasodilators, suggesting an active release process for VIP and ,B-CGRP rather than non-specific passive leakage from anoxic nerve endings. Although the liver is not the major site of peptide metabolism,42 it is possible that hepatic extraction of vasoconstrictors obscured a rise in their plasma concentrations. Indeed, a proportion of portal venous somatostatin is cleared by the liver but the efficiency of this mechanism may be impaired by acidosis43 in ischaemia/reperfusion. Furthermore, different stimuli can release peptide YY, neuropeptide Y, and somatostatin from the splanchnic region into the peripheral circulation30 31 44 thus justifying the use of peripheral plasma for peptide measurement as presently used.
Plasma concentrations of the gut neuropeptide bombesin27 increased during reperfusion especially after an ischaemic interval of 20 minutes, and correlated significantly with VIP and 1-CGRP, consistent with the actions of bombesin in modulating the release of several peptides.6 Bombesin plasma concentrations were comparable with those achieved during exogenous infusion, when significant increases in plasma VIP and enteroglucagon were noted.28 Furthermore, in this study, the actions of bombesin should have been facilitated by the lack of plasma somatostatin response, in view of the antagonistic relation that is reported to exist between the two peptides.6 25 28 Plasma enteroglucagon increased significantly during reperfusion, after each ischaemic interval, and its correlation with plasma bombesin is in line with the proposed role of bombesin in its release.25 28 The correlations of Release of vasodilator, but not vasoconstrictor, neuropeptides and of enteroglucagon by intestinal ischaemia/reperfusion in the rat 1705 plasma enteroglucagon, a gut mucosal peptide, with VIP and 1-CGRP is consistent with the proposition that these neuropeptides were also released from the reperfused intestine. Enteroglucagon was probably released by an active process rather than by passive leakage from damaged cells as brief ischaemic intervals cause intracellular changes only without gross mucosal disruption.24 In addition, passive leakage would have resulted in a rise in plasma peptide YY also. Although these peptides share a similar mucosal distribution,22 41 peptide YY is not a putative trophic hormone,3' a role purported for enteroglucagon. 25 26 The rise in plasma enteroglucagon, whose magnitude depended on the duration of the ischaemic interval and therefore the extent of mucosal damage,24 could be consistent with a trophic role. Mucosal repair begins soon after the onset of reperfusion45 and entails activation of ornithine decarboxylase.46 This enzyme is also activated after bowel resection,47 a state characterised by raised plasma enteroglucagon. 26 The rise in plasma enteroglucagon seen here preceded the reported activation of omithine decarboxylase that follows ischaemia/reperfusion.46 It can therefore be speculated that early release of enteroglucagon may trigger activation of ornithine decarboxylase leading to repair of the injured intestinal mucosa.
In conclusion, we have shown a differential response of gut peptides to intestinal ischaemia/reperfusion. The release of potent vasodilators coincides with reactive hyperaemia whereby exposure of ischaemic tissues to oxygenated blood could lead to reperfusion injury. Enteroglucagon, whose release is proportional to the severity of the ischaemic injury, could participate in subsequent mucosal repair. Bombesin may play a pivotal part by facilitating peptide release. The concerted actions of these peptides, unopposed by vasoconstrictors and somatostatin, may be instrumental in producing the characteristic pathophysiological consequences of intestinal ischaemialreperfusion.
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